| 000 | 01905 a2200553 4500 | ||
|---|---|---|---|
| 005 | 20250516201124.0 | ||
| 264 | 0 | _c20151125 | |
| 008 | 201511s 0 0 eng d | ||
| 022 | _a1718-4304 | ||
| 024 | 7 |
_a10.3747/pdi.2013.00129 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aEvsanaa, Baigalmaa | |
| 245 | 0 | 0 |
_aMgCaCO3 versus CaCO3 in peritoneal dialysis patients--a cross-over pilot trial. _h[electronic resource] |
| 260 |
_bPeritoneal dialysis international : journal of the International Society for Peritoneal Dialysis _c |
||
| 300 |
_a31-4 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Randomized Controlled Trial | ||
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aCalcium Carbonate _xadministration & dosage |
| 650 | 0 | 4 | _aCross-Over Studies |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHyperphosphatemia _xblood |
| 650 | 0 | 4 |
_aMagnesium _xadministration & dosage |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPatient Compliance |
| 650 | 0 | 4 |
_aPeritoneal Dialysis _xadverse effects |
| 650 | 0 | 4 | _aPilot Projects |
| 650 | 0 | 4 | _aRisk Assessment |
| 650 | 0 | 4 | _aSingle-Blind Method |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aLiu, Irene | |
| 700 | 1 | _aAliazardeh, Babak | |
| 700 | 1 | _aMahdavi, Sara | |
| 700 | 1 | _aBajwa, Gursarn | |
| 700 | 1 | _aGula, Jerry | |
| 700 | 1 | _aTam, Michelle | |
| 700 | 1 | _aSze, Elena | |
| 700 | 1 | _aRoscoe, Janet M | |
| 700 | 1 | _aTam, Paul Y | |
| 700 | 1 | _aSikaneta, Tabo | |
| 773 | 0 |
_tPeritoneal dialysis international : journal of the International Society for Peritoneal Dialysis _gvol. 35 _gno. 1 _gp. 31-4 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.3747/pdi.2013.00129 _zAvailable from publisher's website |
| 999 |
_c23599867 _d23599867 |
||